Search
Oxypurinol
go.drugbank.com/drugs/DB05262InvestigationalOxypurinol, an inhibitor of xanthine oxidase, is a metabolite of allopurinol.
Luliconazole
go.drugbank.com/drugs/DB08933ApprovedInvestigationalIt was approved by the FDA (USA) in November 2013 and is marketed under the brand name Luzu. Luliconazole is also approved in Japan. … Luliconazole is a topical antifungal agent that acts by unknown mechanisms but is postulated to involve altering the synthesis of fungi cell membranes.
Vapreotide
go.drugbank.com/drugs/DB04894InvestigationalVapreotide is a synthetic octapeptide somatostatin analog. It was being studied for the treatment of cancer.
DCLL-9718S
go.drugbank.com/drugs/DB17392InvestigationalDCLL9718S is under investigation in clinical trial NCT03298516 (A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine … DCLL9718S is an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1).
JNJ-42165279
go.drugbank.com/drugs/DB15173InvestigationalJnj-42165279 is under investigation in clinical trial NCT02498392 (An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress).
Tesaglitazar
go.drugbank.com/drugs/DB06536InvestigationalTesaglitazar is a dual peroxisome proliferator-activated receptor alpha/gamma agonist which improves apolipoprotein levels in non-diabetic subjects with insulin resistance. … Tesaglitazar is a proposed treatment for type 2 diabetes and has completed several phase III clinical trials, however in May 2006 AstraZeneca announced that they had discontinued further development.
Tifenazoxide
go.drugbank.com/drugs/DB21402InvestigationalTifenazoxide is a small molecule drug. Tifenazoxide is under investigation in clinical trial NCT04744129 (Headache Inducing Effect of NN414 in Migraine Patients). … Tifenazoxide has a monoisotopic molecular weight of 290.99 Da.
Eprinomectin
go.drugbank.com/drugs/DB11405ExperimentalVet approvedCategories: Compounds used in a research, industrial, or household settingSuccinobucol
go.drugbank.com/drugs/DB05399InvestigationalAGI-1067, is a novel small molecule with anti-oxidant and anti-inflammatory properties that was discovered by AtheroGenics and designed to treat atherosclerosis of the blood vessels of the heart, or coronary
M0002
go.drugbank.com/drugs/DB05091InvestigationalM0002 is an orally-active selective vasopressin antagonist that inhibits water re-absorption from the kidneys. … It is a vasopressin 2 antagonist and represents a new class of compounds – aquaretics – that produce profound diuresis without loss of electrolytes.